EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EyePoint Pharmaceuticals reports revenue growth and strategic expansion plans

EyePoint Pharmaceuticals showcased strong revenue growth, promising product pipeline with EYP-1901, and strategic partnerships for future expansion. While facing challenges in trial design and molecule size for sustained release, the company is well-positioned for growth with opportunities for collaborations and improved margins in 2023.

EyePoint Pharmaceuticals reports strong Q1 performance and advances revolutionary eye disease treatment

EyePoint Pharmaceuticals (EYPT) delivered a strong Q1 2023 performance, driven by progress in clinical trials for EYP-1901 and a robust YUTIQ franchise.
The company's focus on innovation, safety, and market needs positions EYP-1901 as a potential game-changer in treating chronic eye diseases.
While challenges exist in trial modifications and regulatory considerations, opportunities abound in market expansion, collaboration potential, and regulatory progress.
Overall, EyePoint Pharmaceuticals (EYPT) showcases promising growth prospects and a commitment to advancing novel treatments for retinal diseases.

EyePoint Pharmaceuticals reports Q2 revenue growth amidst operational challenges

EyePoint Pharmaceuticals' Q2 2023 performance showed revenue growth but with significant operating expenses leading to a net loss.
Strengths lie in the progress of EYP-1901, positive data presentations, and a well-capitalized position for future endeavors.
Challenges include financial losses, concerns about patient response variability, and Phase III trial design complexities.
Opportunities exist in exploring funding avenues, post-approval studies, and strategic cost management for Phase III trials.

EyePoint Pharmaceuticals reports Q3 revenue growth and advances drug pipeline

EyePoint Pharmaceuticals showcased progress in drug development and revenue generation in Q3 2023.
The company is strategically positioned with a strong cash position to fund operations into 2025.
Focus on innovative drug delivery mechanisms and collaborations for sustained release treatments.

EyePoint Pharmaceuticals excels in Q4, poised for retinal disease innovation

EyePoint Pharmaceuticals delivered strong financial results, showcased promising trial outcomes for EYP-1901 in wet AMD, and addressed key analyst inquiries regarding market dynamics and competition. With a focus on innovation and strategic leadership appointments, the company is poised for transformative developments in retinal disease treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EyePoint Pharmaceuticals (EYPT) stock is heading higher on Monday thanks to interim results from a Phase 1 clinical trial. The post EYPT Stock: The Clinical Trial News That Has EyePoint Pharma Investors Seeing Green Today appeared first on InvestorPlace.

EYPT Stock: The Clinical Trial News That Has EyePoint Pharma Investors Seeing Green Today

WATERTOWN, Mass., Nov. 13, 2021 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the "Durasert® and Vorolanib in Ophthalmology" (DAVIO) Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting wet age-related macular degeneration (wet AMD).

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that management will host a conference call to highlight interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD on Saturday, November 13 at 12:00 P.M. ET/11:00 A.M. CST. Dr. Carl Regillo, KOL and Chair of the Company's Scientific Advisory Board, will be participating in the live event.

EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call Transcript

– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) –

EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO). Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoint's Board of Directors since 2016. In his new full-time role as COO, Dr. Duker will be responsible for overseeing all clinical development, research, product development and manufacturing.

EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D.

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 3, 2021 to report its third quarter 2021 financial results and discuss recent business highlights.

EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021

– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD –

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting

Photo Credit: EyePoint Pharmaceuticals Companies dedicated to improving the lives of the 2.2 billion people suffering from eye diseases are making incredible strides in developing new therapeutics. One of those companies, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), is progressing its pipeline – which is entirely focused on addressing the most serious disorders impacting eyesight – in part through the ongoing Phase 1 DAVIO trial of its proprietary EYP-1901.

EyePoint Sets its Sights on Developing Treatments Improving the Lives of Eye Disease Sufferers

WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901 in wet AMD has been selected for presentation at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting to be held from November 12 – 15, 2021.

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

Alcon Inc. - Registered Shares

Cooper Companies

National Vision Hlds

Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.

4 Stocks to Keep a Watch on Amid Growing Optical Care Demand

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2021 Results - Earnings Call Transcript

Positive 30-Day Safety Data Reported for EYP-1901 DAVIO study for the potential treatment of wet AMD; study remains on track for initial readout in Q4 2021

EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Chaired by Dr. Carl Regillo, illustrious leader in retinal surgery Chaired by Dr. Carl Regillo, illustrious leader in retinal surgery

EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

WATERTOWN, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 4, 2021 to report its second quarter 2021 financial results and discuss recent business highlights.

EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021

WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company expects to receive a nine month extension on DEXYCU®'s pass-through payment status, which otherwise would expire on March 31, 2022.

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel accepted the addition of a new Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022, providing an opportunity for a reimbursement pathway for the administration of DEXYCU.

EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association

WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the US market opens on June 28, 2021 as a result of the annual Russell index reconstitution.

EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index

WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Jefferies Healthcare Conference on June 2, 2021 at 9:30 a.m. ET.

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

WATERTOWN, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the completion of patient enrollment of its Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call Transcript

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 5.66% and -11.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates

EYP-1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January; study remains on track for initial data in Q4 2021

EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments

On Wednesday, May 05, EyePoint Pharmaceuticals (NASDAQ:EYPT) will release its latest earnings report. Decipher the announcement with Benzinga's help.

News for EyePoint Pharmaceuticals Stock (EYPT)